UARK 2005-01, A Phase III Study of Velcade, Thalidomide, and Dexamethasone (VTD) With or Without Adriamycin® in Relapsed/Refractory Patients
In this study, there will be two arms (or groups). One arm will receive Velcade,
thalidomide, and dexamethasone (VTD), and the other arm will receive VTD with Adriamycin.
This study has the following specific goal:
To evaluate the efficacy and toxicity of two treatments in multiple myeloma patients,
relapsing after at least one course of high-dose treatment and an autologous stem cell
transplant, or after at least two lines of conventional chemotherapy.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Evaluate the effectiveness of the combination of these drugs
Klaus Hollmig, MD
University of Arkansas
United States: Food and Drug Administration
|University of Arkansas for Medical Sciences||Little Rock, Arkansas 72205|